160 related articles for article (PubMed ID: 35381793)
1. Erythroderma: An unusual manifestation of imatinib - A rare case report.
Kataria P; Patel A; Kendre P; Tahiliani N; Mule T; Bohra M
J Cancer Res Ther; 2022; 18(1):253-256. PubMed ID: 35381793
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate induced erythroderma: A rare case series.
Kumar S; Mahajan BB; Kaur S; Banipal RP; Singh A
J Cancer Res Ther; 2015; 11(4):993-6. PubMed ID: 26881566
[TBL] [Abstract][Full Text] [Related]
3. Imatinib Mesylate Induced Erythroderma.
Lunge S; Bhise R
J Assoc Physicians India; 2018 Dec; 66(12):79-80. PubMed ID: 31313559
[TBL] [Abstract][Full Text] [Related]
4. Indications for imatinib mesylate therapy and clinical management.
Guilhot F
Oncologist; 2004; 9(3):271-81. PubMed ID: 15169982
[TBL] [Abstract][Full Text] [Related]
5. A rare case of imatinib-induced erythroderma.
Verma R; Vasudevan B; Pragasam V; Neema S
Indian J Pharmacol; 2013; 45(6):634-5. PubMed ID: 24347779
[TBL] [Abstract][Full Text] [Related]
6. Imatinib Mesylate.
Waller CF
Recent Results Cancer Res; 2018; 212():1-27. PubMed ID: 30069623
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
8. Skin lesions in patients treated with imatinib mesylate: a 5-year prospective study.
Paolino G; Didona D; Clerico R; Corsetti P; Ambrifi M; Bottoni U; Calvieri S
Cutis; 2016 Jun; 97(6):E12-6. PubMed ID: 27416091
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up.
Dervis E; Ayer M; Akin Belli A; Barut SG
Eur J Dermatol; 2016 Apr; 26(2):133-7. PubMed ID: 26679005
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate.
Waller CF
Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
[TBL] [Abstract][Full Text] [Related]
11. A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours.
Wolf D; Rumpold H
Drug Saf; 2009; 32(11):1001-15. PubMed ID: 19810774
[TBL] [Abstract][Full Text] [Related]
12. Hyperpigmentation due to imatinib: A rare case of cutaneous involvement.
Rehman H; Hakim N; Sugarman R; Seetharamu N; Saif MW
J Oncol Pharm Pract; 2020 Sep; 26(6):1511-1515. PubMed ID: 32067560
[TBL] [Abstract][Full Text] [Related]
13. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
14. Imatinib-induced Stevens-Johnsons syndrome.
Jha P; Himanshu D; Jain N; Singh AK
BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23349042
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate induced erythroderma.
Sanghavi SA; Dongre AM; Khopkar US
Indian J Dermatol Venereol Leprol; 2012; 78(3):408. PubMed ID: 22565463
[No Abstract] [Full Text] [Related]
16. Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
[TBL] [Abstract][Full Text] [Related]
17. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
18. Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate.
Brazzelli V; Muzio F; Manna G; Moggio E; Vassallo C; Orlandi E; Fiandrino G; Lucioni M; Borroni G
Photodermatol Photoimmunol Photomed; 2012 Feb; 28(1):2-5. PubMed ID: 22211996
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
20. The safety profile of imatinib in CML and GIST: long-term considerations.
Thanopoulou E; Judson I
Arch Toxicol; 2012 Jan; 86(1):1-12. PubMed ID: 21717109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]